2009 · 16 citations · 20 references
PharmacyHealth PolicyPharmacoeconomicsComparative Effectiveness ResearchCost-effectiveness AnalysisHealth Services ResearchComparative Effectiveness AssessmentCost-effectiveness ComparisonEvidence-based MedicinePharmacoeconomic EvaluationPrescription Drug CoveragePrescription Drug PolicyCoverage Decision FrameworksCoverage For PharmaceuticalsDrug Coverage AssessmentEvidence-based Coverage DeterminationInsurance Coverage Of Medicines
Context National public insurance for drugs is often based on evidence of comparative effectiveness and cost-effectiveness. This study describes how that evidence has been used across 3 jurisdictions (Australia, Canada, and Britain) that have been at the forefront of evidence-based coverage internationally.
20
Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?
Robert Temple · JAMA · 1999 · 340 citations
Medicine, Cardiology, Neurology +9
Problems With the Interpretation of Pharmacoeconomic Analyses
Suzanne Hill, Andrew Mitchell, David Henry · JAMA · 2000 · 228 citations